Format

Send to

Choose Destination
Drug Discov Today. 2016 Mar;21(3):481-90. doi: 10.1016/j.drudis.2016.02.001. Epub 2016 Feb 8.

Multidrug co-crystals: towards the development of effective therapeutic hybrids.

Author information

1
Solid State Pharmaceutical Research Group (SSPRG), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.
2
Solid State Pharmaceutical Research Group (SSPRG), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India; Solid State Pharmaceutical Cluster (SSPC), School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, The University of Dublin, Ireland.
3
Solid State Pharmaceutical Research Group (SSPRG), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India. Electronic address: nalini.niperhyd@gov.in.

Abstract

Co-crystals have garnered the interest of the pharmaceutical industry with the introduction of regulatory guidelines by the US Food and Drug Administration (FDA) as a result of expanded patent portfolios. The Phase II clinical success of tramadol and celecoxib co-crystal for the treatment of acute pain followed by a recent reflection paper published by the European Medicines Agency (EMA) have further boosted the development of drug-drug co-crystals. Here, we shed light on the developments of drug-drug co-crystals and highlight future perspectives for exploring new therapeutic hybrids deploying drug-drug, drug-nutraceuticals and drug-inorganic salt combinations with improved pharmaceutical and biopharmaceutical performance.

PMID:
26869329
DOI:
10.1016/j.drudis.2016.02.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center